KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.

Myrtle F Krul, Niels F M Kok, Harun Osmani, Florian E Buisman, Bas Groot Koerkamp, Dirk J Grunhagen, Cornelis Verhoef, Bianca Mostert, Petur Snaebjornsson, Bram Westerink, Elisabeth G Klompenhouwer, Maarten L Donswijk, Theo J M Ruers, Joeri A J Douma, Nico van Blijderveen, T Peter Kingham, Michael I D'Angelica, Nancy E Kemeny, Karen Bolhuis, Tineke E Buffart, Koert F D Kuhlmann

Br J Surg 111(4) znae089

PMID38608150
PMCID-
DOI10.1093/bjs/znae089
发表日期2024-04-12
入排依据:The study is a single-arm Phase II feasibility trial, not a randomized Phase III/IIIb or Phase II/III trial. It lacks a randomized control group. The primary endpoint is feasibility (completion of cycles), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The publication type includes 'Clinical Trial, Phase II' and the abstract explicitly states it is a single-arm Phase II study. A subsequent Phase III randomized trial is mentioned as a future direction but is not the subject of this report.
摘要

摘要

BACKGROUND: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS) for liver-only colorectal liver metastases (CRLMs) has shown promising results but has not been adopted worldwide. This study evaluated the feasibility of HAIP-SYS in the Netherlands. METHODS: This was a single-arm phase II study of patients with CRLMs who received HAIP-SYS consisting of floxuridine with concomitant systemic FOLFOX or FOLFIRI. Main inclusion and exclusion criteria were borderline resectable or unresectable liver-only metastases, suitable arterial anatomy and no previous local treatment. Patients underwent laparotomy for pump implantation and primary tumour resection if in situ. Primary end point was feasibility, defined as ≥70% of patients completing two cycles of HAIP-SYS. Sample size calculations led to 31 patients. Secondary outcomes included safety and tumour response. RESULTS: Thirty-one patients with median 13 CRLMs (i.q.r. 6-23) were included. Twenty-eight patients (90%) received two HAIP-SYS cycles. Three patients did not get two cycles due to extrahepatic disease at pump placement, definitive pathology of a recto-sigmoidal squamous cell carcinoma, and progressive disease. Five patients experienced grade 3 surgical or pump device-related complications (16%) and 11 patients experienced grade ≥3 chemotherapy toxicity (38%). At first radiological evaluation, disease control rate was 83% (24/29 patients) and hepatic disease control rate 93% (27/29 patients). At 6 months, 19 patients (66%) had experienced grade ≥3 chemotherapy toxicity and the disease control rate was 79%. CONCLUSION: HAIP-SYS for borderline resectable and unresectable CRLMs was feasible and safe in the Netherlands. This has led to a successive multicentre phase III randomized trial investigating oncological benefit (EUDRA-CT 2023-506194-35-00). Current trial registration number: clinicaltrials.gov (NCT04552093).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。